<DOC>
	<DOCNO>NCT02733185</DOCNO>
	<brief_summary>Trial Assess Chelation Therapy 2 ( TACT2 ) randomize , double blind control factorial clinical trial edetate disodium-based chelation high-dose oral vitamin mineral prevent recurrent cardiac event diabetic patient prior myocardial infarction ( MI ) .</brief_summary>
	<brief_title>Trial Assess Chelation Therapy 2</brief_title>
	<detailed_description>The primary objective TACT2 , therefore , determine chelation-based strategy increase time first occurrence component TACT2 primary endpoint : all-cause mortality , myocardial infarction , stroke , coronary revascularization , hospitalization unstable angina compare placebo chelation strategy . TACT2 2x2 factorial trial test 40-weekly edetate disodium-based chelation infusion twice daily high-dose oral multivitamin multiminerals ( OMVM ) placebo-controlled design . TACT2 carry replicate finding TACT1 , find strike reduction recurrent cardiovascular event post-MI diabetic patient receive edetate disodium-based chelation therapy .</detailed_description>
	<mesh_term>Infarction</mesh_term>
	<mesh_term>Myocardial Infarction</mesh_term>
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Edetic Acid</mesh_term>
	<mesh_term>Pentetic Acid</mesh_term>
	<criteria>1 . Age : â‰¥ 50 year 2 . History diabetes , define medical record evidence patient report currently use insulin oral hypoglycemic agent , history fast blood glucose measurement 126 mg/dL high , history HbA1c 6.5 % high . 3 . History myocardial infarction base Universal Definition MI . 36 1 . When information MI hospitalization available , MI type except Type 2 qualify study entry . 2 . When information MI hospitalization available , wall motion abnormality image perfusion defect scan corresponds coronary distribution , whether accompanied pathological Q wave appropriate distribution , qualify patient study entry . This criterion require call CCC case review . 1 . Baseline serum creatinine &gt; 2.0 mg/dL . 2 . HbA1C &gt; 11 % . 3 . Myocardial infarction within 6 week randomization . 4 . History allergic reaction EDTA component chelation solution , include heparin . 5 . Coronary peripheral arterial revascularization procedure perform within last 6 month . 6 . Planned revascularization procedure 6 month follow enrollment . 7 . Heart failure hospitalization within 6 month prior enrollment clinical heart failure time propose enrollment ( NYHA Class 3 dyspnea + rales &gt; basilar , additional sign fluid overload ) . Such patient may treat diuretic enrol stable . 8 . Poor venous access upper extremity . 9 . Prior intravenous chelation therapy within 5 year oral chelation within 2 year time propose randomization . 10 . Prior participation TACT1 . 11 . Baseline platelet count &lt; 100,000 . 12 . History cigarette smoking within last 3 month . 13 . ALT AST &gt; 2.0 time upper limit normal . 14 . Wilson 's disease , hemochromatosis , parathyroid disease . 15 . Any medical condition include current diagnosis cancer ( except nonmelanoma skin cancer ) limit patient survival duration trial . 16 . Any factor suggest potential participant able adhere protocol . 17 . Women childbearing potential include plan postmenopausal vitro fertilization reproductive technology .</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>chelation</keyword>
</DOC>